AMAndrew Menzies-Gow

Andrew Menzies-Gow

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andrew Menzies-Gow has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Disease manifestations and costs of idiopathic hypereosinophilic syndrome: perspectives from Europe

    by Florence Roufosse, Antoine Bondue, Matthieu Groh, Martin Metz, Christoph Schlag, Juliana Schwaab, Salman Siddiqui, Jean-François Viallard, Chris Edmonds, Jennifer Rowell, et al.

  • Open Access

    Early and Sustained Asthma Control and Remission in Real‐World Patients With Severe Eosinophilic Asthma Treated With Benralizumab: XALOC ‐2

    by Erika Penz, Thomas Rothe, Lieven Dupont, Trung N. Tran, Andrew Menzies‐Gow, Anat Shavit, David Cohen, Tanja Plate, Sheena Kayaniyil, An Herreman, et al.

    Background: Prospective real‐world data concerning the early and sustained effects of benralizumab on asthma control in patients with severe eosinophilic asthma ( SEA ) is lacking. Methods: XALOC ‐2 is a prospective, observational, multi‐national, real‐world study in adults with SEA treated with benralizumab. This integrated analysis assessed Asthma Control Questionnaire ( ACQ ) scores, achievement of 3‐component clinical remission (which included well‐controlled symptoms [ ACQ score ≤ 0.75], no exacerbations, and no use of maintenance oral corticosteroids [ mOCS ]), and other clinical outcomes, over a 12‐month baseline period and up to Week 56. Associations between remission status and key baseline characteristics were also assessed. Results: 535 patients were included. Median (interquartile range) ACQ score at baseline was 3.0 (2.2–3.8). At Week 1, 58.0% (282/486) of patients had ACQ score reductions of ≥ 0.5 points (minimal clinically important difference [ MCID ]) and 35.0% (170/486) had reductions of ≥ 1 point (2× MCID ). By Week 56, these increased to 78.6% (276/351) and 62.1% (218/351), respectively. Improved asthma control after benralizumab initiation was similar irrespective of previous biologic use status. By Week 56, clinical remission criteria were achieved in 26.7% (70/262) of patients versus 0% (0/374) at baseline. No mOCS use, lower body mass index, better asthma symptom control and higher peak blood eosinophil count at baseline were associated with meeting 3‐component clinical remission criteria at Week 56. Conclusions: Real‐world patients receiving benralizumab showed early and sustained improvements in asthma symptoms, regardless of previous biologic use. More than a quarter of patients achieved clinical asthma remission after 1 year of benralizumab treatment.


  • Open Access

    Advancing Remission in Severe Asthma With Benralizumab: Latest Findings, Current Perspectives and Future Direction

    by Renaud Louis, Marek Lommatzsch, David J. Jackson, Andrew Menzies‐Gow, Anat Shavit, David Cohen, Flavia C. L. Hoyte, Stephanie Korn

    The introduction of biologics, such as benralizumab (an anti‐IL‐5 receptor α humanised monoclonal antibody), has made remission a feasible goal for patients with severe eosinophilic asthma (SEA). However, there are remaining research gaps and no clear consensus on the definition of remission. We consolidated post hoc remission data from clinical trials and real‐world studies of benralizumab in patients with SEA to gather insights on: testing different definitions; predictors of remission; the effect of comorbidities on achieving remission; remission and background medication reduction; long‐term remission patterns with benralizumab; and remission in a real‐life setting. In the SIROCCO and CALIMA Phase 3 randomised studies, patients with remission had higher baseline median blood eosinophil counts, were more likely to have a FEV 1 of ≥ 65% predicted, had fewer exacerbations within 12 months and had lower mean ACQ‐6 scores. Compared with the overall population, patients with a history of nasal polyps were also more likely to achieve remission with benralizumab. Analyses of the BORA and MELTEMI extension studies showed that in the longer term, once remission is achieved with benralizumab, patients are likely to remain in remission with continued treatment. In the open‐label, single‐arm ANDHI‐In Practice and PONENTE studies, patients achieving remission had a shorter median time since asthma diagnosis, higher median age at asthma onset and lower median ACQ‐6 scores. The SHAMAL study and the Phase 3b ANDHI‐In Practice substudy demonstrate that remission is maintained with benralizumab even when patients reduce their background medication. Finally, the XALOC‐1 real‐world study highlights how patients with lower BMI are more likely to achieve remission with benralizumab. These findings demonstrate that achieving remission in patients with SEA is feasible with benralizumab and, in turn, inform future directions for research and treatment that includes a promising shift towards a new era of treat‐to‐target. This manuscript was supported by AstraZeneca, the manufacturer of benralizumab.


  • Open Access

    International Severe Asthma Registry (ISAR): 2017–2024 Status and Progress Update

    by Désirée Larenas-Linnemann, Chin Kook Rhee, Alan Altraja, John Busby, Trung N. Tran, Eileen Wang, Todor A. Popov, Patrick D. Mitchell, Paul E. Pfeffer, Roy Alton Pleasants, et al.

    The International Severe Asthma Registry (ISAR) was established in 2017 to advance the understanding of severe asthma and its management, thereby improving patient care worldwide. As the first global registry for adults with severe asthma, ISAR enabled individual registries to standardize and pool their data, creating a comprehensive, harmonized dataset with sufficient statistical power to address key research questions and knowledge gaps. Today, ISAR is the largest repository of real-world data on severe asthma, curating data on nearly 35,000 patients from 28 countries worldwide, and has become a leading contributor to severe asthma research. Research using ISAR data has provided valuable insights on the characteristics of severe asthma, its burdens and risk factors, real-world treatment effectiveness, and barriers to specialist care, which are collectively informing improved asthma management. Besides changing clinical thinking via research, ISAR aims to advance real-world practice through initiatives that improve registry data quality and severe asthma care. In 2024, ISAR refined essential research variables to enhance data quality and launched a web-based data acquisition and reporting system (QISAR), which integrates data collection with clinical consultations and enables longitudinal data tracking at patient, center, and population levels. Quality improvement priorities include collecting standardized data during consultations and tracking and optimizing patient journeys via QISAR and integrating primary/secondary care pathways to expedite specialist severe asthma management and facilitate clinical trial recruitment. ISAR envisions a future in which timely specialist referral and initiation of biologic therapy can obviate long-term systemic corticosteroid use and enable more patients to achieve remission.


  • Open Access

    Real‐world biologics response and super‐response in the International Severe Asthma Registry cohort

    by Eve Denton, Mark Hew, Matthew J. Peters, John W. Upham, Lakmini Bulathsinhala, Trung N. Tran, Neil Martin, Celine Bergeron, Mona Al‐Ahmad, Alan Altraja, et al.

    Background: Biologic asthma therapies reduce exacerbations and long‐term oral corticosteroids (LTOCS) use in randomized controlled trials (RCTs); however, there are limited data on outcomes among patients ineligible for RCTs. Hence, we investigated responsiveness to biologics in a real‐world population of adults with severe asthma. Methods: Adults in the International Severe Asthma Registry (ISAR) with ≥24 weeks of follow‐up were grouped into those who did, or did not, initiate biologics (anti‐IgE, anti‐IL5/IL5R, anti‐IL4/13). Treatment responses were examined across four domains: forced expiratory volume in 1 second (FEV 1 ) increase by ≥100 mL, improved asthma control, annualized exacerbation rate (AER) reduction ≥50%, and any LTOCS dose reduction. Super‐response criteria were: FEV 1 increase by ≥500 mL, new well‐controlled asthma, no exacerbations, and LTOCS cessation or tapering to ≤5 mg/day. Results: 5.3% of ISAR patients met basic RCT inclusion criteria; 2116/8451 started biologics. Biologic initiators had worse baseline impairment than non‐initiators, despite having similar biomarker levels. Half or more of initiators had treatment responses: 59% AER reduction, 54% FEV 1 increase, 49% improved control, 49% reduced LTOCS, of which 32%, 19%, 30%, and 39%, respectively, were super‐responses. Responses/super‐responses were more frequent in biologic initiators than in non‐initiators; nevertheless, ~40–50% of initiators did not meet response criteria. Conclusions: Most patients with severe asthma are ineligible for RCTs of biologic therapies. Biologics are initiated in patients who have worse baseline impairments than non‐initiators despite similar biomarker levels. Although biologic initiators exhibited clinical responses and super‐responses in all outcome domains, 40–50% did not meet the response criteria.


  • Impact of sex on severe asthma: a cross-sectional retrospective analysis of UK primary and specialist care

    by Lola Loewenthal, John Busby, Ronald McDowell, Thomas Brown, Hassan Burhan, Rekha Chaudhuri, Paddy Dennison, James William Dodd, Simon Doe, Shoaib Faruqi, et al.

    Introduction: After puberty, females are more likely to develop asthma and in a more severe form than males. The associations between asthma and sex are complex with multiple intrinsic and external factors.Aim: To evaluate the sex differences in the characteristics and treatment of patients with severe asthma (SA) in a real-world setting.Methods: Demographic, clinical and treatment characteristics for patients with SA in the UK Severe Asthma Registry (UKSAR) and Optimum Patient Care Research Database (OPCRD) were retrospectively analysed by sex using univariable and multivariable logistic regression analyses adjusted for year, age and hospital/practice.Results: 3679 (60.9% female) patients from UKSAR and 18 369 patients (67.9% female) from OPCRD with SA were included. Females were more likely to be symptomatic with increased Asthma Control Questionnaire-6 (UKSAR adjusted OR (aOR) 1.14, 95% CI 1.09 to 1.18) and Royal College of Physicians-3 Question scores (OPCRD aOR 1.29, 95% CI 1.13 to 1.47). However, they had a higher forced expiratory volume in 1 second per cent (FEV1%) predicted (UKSAR 68.7% vs 64.8%, p1% predicted and lower type 2 biomarkers with consistent and clinically important differences across both datasets.


  • Clinical Remission in Severe Asthma

    by Andrew N. Menzies-Gow, David B. Price


  • Open Access

    Effect of tezepelumab on healthcare utilization in patients with severe, uncontrolled asthma

    by Andrew Menzies-Gow, Arnaud Bourdin, Geoffrey Chupp, Elliot Israel, Åsa Hellqvist, Gillian Hunter, Stephanie L. Roseti, Christopher S. Ambrose, Jean-Pierre Llanos, Bill Cook, et al.


  • Open Access

    Adrenal function recovery after durable oral corticosteroid sparing with benralizumab in the PONENTE study

    by Andrew Menzies-Gow, Mark Gurnell, Liam G. Heaney, Jonathan Corren, Elisabeth H. Bel, Jorge Maspero, Timothy Harrison, David J. Jackson, David Price, Njira Lugogo, et al.

    Background: Oral corticosteroid (OCS) dependence among patients with severe eosinophilic asthma can cause adverse outcomes, including adrenal insufficiency. PONENTE's OCS reduction phase showed that, following benralizumab initiation, 91.5% of patients eliminated corticosteroids or achieved a final dosage ≤5 mg·day−1(median (range) 0.0 (0.0–40.0) mg).Methods: The maintenance phase assessed the durability of corticosteroid reduction and further adrenal function recovery. For ∼6 months, patients continued benralizumab 30 mg every 8 weeks without corticosteroids or with the final dosage achieved during the reduction phase. Investigators could prescribe corticosteroids for asthma exacerbations or increase daily dosages for asthma control deteriorations. Outcomes included changes in daily OCS dosage, Asthma Control Questionnaire (ACQ)-6 and St George's Respiratory Questionnaire (SGRQ), as well as adrenal status, asthma exacerbations and adverse events.Results: 598 patients entered PONENTE; 563 (94.1%) completed the reduction phase and entered the maintenance phase. From the end of reduction to the end of maintenance, the median (range) OCS dosage was unchanged (0.0 (0.0–40.0) mg), 3.2% (n=18/563) of patients experienced daily dosage increases, the mean ACQ-6 score decreased from 1.26 to 1.18 and 84.5% (n=476/563) of patients were exacerbation free. The mean SGRQ improvement (–19.65 points) from baseline to the end of maintenance indicated substantial quality-of-life improvements. Of patients entering the maintenance phase with adrenal insufficiency, 32.4% (n=104/321) demonstrated an improvement in adrenal function. Adverse events were consistent with previous reports.Conclusions: Most patients successfully maintained maximal OCS reduction while achieving improved asthma control with few exacerbations and maintaining or recovering adrenal function.